Skip to main content
. 2023 Dec 14;9:165. doi: 10.1038/s41531-023-00612-y

Table 1.

Clinical characteristics and plasma concentrations of microbial metabolites in participants.

Healthy controls (N = 250) PD patients (N = 250) P-value
Age (years) 67.4 ± 7.5 67.4 ± 7.7 0.95
Sex (male), n (%) 165 (66.0) 164 (65.6) 0.93
BMI 22.6 ± 1.4 22.6 ± 1.5 0.99
Constipation, n (%) 103 (41.2) 130 (52.0) 0.01*
Creatinine (mg/dL) 0.9 ± 0.3 0.9 ± 0.2 0.96
Disease duration (years) N.A. 7.4 ± 2.4
Hoehn-and-Yahr stage N.A. 3.2 ± 0.9
Early-stage, n (%) N.A. 46 (18.4%)
Advanced-stage, n (%) N.A. 204 (81.6%)
MDS-UPDRS part III N.A. 35.0 ± 9.9
MMSE 28.7 ± 1.8 26.5 ± 2.7 <0.01**
LEDD N.A. 649.2 ± 206.0
Plasma metabolites (ng/mL)
 Phenylalanine (PHE) 9733.7 ± 1868.1 9674.9 ± 2252.9 0.50
 Phenylacetic acid (PAA) 81.9 ± 106.1 113.7 ± 82.9 <0.001***
 Phenylacetylglutamine (PAGln) 849.1 ± 2778.0 1024.3 ± 1025.6 <0.001***
 Phenyllactic acid (PLA) 26.7 ± 15.1 30.3 ± 18.7 0.02*
 Phenylpropionic acid (PPA) 28.8 ± 40.6 61.5 ± 122.7 <0.001***
 P-cresol sulfate (Pcs) 2110.7 ± 2603.1 3265.1 ± 2899.3 <0.001***
 P-cresol glucuronide (Pcg) 25.2 ± 101.8 41.5 ± 61.5 <0.001***
 Indoxyl sulfate (IS) 1059.8 ± 2838.7 1132.2 ± 1380.6 <0.001***
Medical co-morbidity, n (%)
 Diabetes mellitus 61 (24.4) 49 (19.6) 0.19
 Hypertension 68 (27.2) 53 (21.2) 0.12
 History of cardiovascular disease 40 (16.0) 31 (12.4) 0.25
 History of stroke 32 (12.8) 23 (9.2) 0.19

Variables are expressed as mean ± standard deviation or number (percentage).

BMI body mass index, IS indoxyl sulfate, LEDD levodopa equivalent daily dose, MDS-UPDRS Movement Disorder Society Unified PD Rating Scale, MMSE Mini-Mental State Examination, N.A. not available, Pcg p-Cresol glucuronide, Pcs p-Cresol sulfate, PAA phenylacetic acid, PAGln phenylacetylglutamine, PHE phenylalanine, PLA phenyllactic acid, PPA phenylpropionic acid. *P < 0.05; **P < 0.01; ***P < 0.001.